Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23030132 | 0.86 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL8466087 | 0.85 | TSHR (0.48) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL1006539 | 0.82 | CYP1A2 (0.45) | CD44CYP3A4TSHRGRIN2DGRIN3B | |
| SCHEMBL8439291 | 0.81 | CD44 (0.52) | CD44CYP3A4TDP1TSHRPIK3CA | |
| Benzene SCHEMBL28199279 | 0.79 | CYP1A2 (0.43) | CYP3A4TSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27839905 | 0.79 | CYP1A2 (0.43) | CD44CYP3A4TSHRGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL2864880 | 0.79 | CYP1A2 (0.43) | CD44CYP3A4TDP1TSHRGRIN2D | |
| SCHEMBL20120116 | 0.79 | CD44 (0.50) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL15089832 | 0.78 | CYP3A4 (0.37) | CD44CYP3A4TDP1TSHRPIK3CA | |
| SCHEMBL11779941 | 0.76 | CYP3A4 (0.40) | CD44CYP3A4TDP1TSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779108-A | 3- (2,3- dihydro -1H- indenes -5- bases) propanoic derivatives and their purposes as NRF2 conditioning agents | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-108137557-A | Nrf2 modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2016134145-A9 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| CN-101155787-B | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| CN-101155787-A | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| WO-2007115077-A2 | BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192169-A1 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | CD44 4455/4885CYP3A4 1310/4885TDP1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.